- Pöllinger B, Haiderali A, Huang M, Akyol Ersoy B, Abdelaziz AH, Kassem L, Elsisi GH. The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab. J Med Econ. 2025 Dec;28(1):105-113. doi: 10.1080/13696998.2024.2441073. Epub 2025 Jan 3. PMID: 39665251.
- Elsisi, G. H., Waleed, A. A., Shehhy, W. A., & Farghaly, M. (2024). Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates. Journal of medical economics, 27(sup1), 23–34.
- Elsisi, G. H., Quintana, G., Gil, D., Santos, P., & Fernandez, D. (2024). Clinical and economic burden of systemic lupus erythematosus in Colombia. Journal of medical economics, 27(sup1), 1–11.
- Elsisi, G. H., Hsieh, S. C., & Chen, D. Y. (2024). The economic burden of systemic lupus erythematosus in Taiwan. Journal of medical economics, 27(sup1), 56–66.
- Alansari, A., Hannawi, S., Aldhaheri, A., Zamani, N., Elsisi, G. H., Aldalal, S., Naeem, W. A., & Farghaly, M. (2024). The economic burden of systemic lupus erythematosus in United Arab Emirates. Journal of medical economics, 27(sup1), 35–45.
- Elsisi, G. H., Joe, A. Y., Zain, M. M., Yusoof, H. M., Teh, C. L., Mohd, A. B., Khor, X. T., & Isa, L. B. M. (2024). Economic burden of systemic lupus erythematosus in Malaysia. Journal of medical economics, 27(sup1), 46–55.
- Elsisi, G. H., Andrade-Ortega, L., Portela, M., & Ramírez, G. M. (2024). The economic burden of systemic lupus erythematosus in Mexico. Journal of medical economics, 27(sup1), 12–22.
- Elsisi G, Ezzat M, Ramadan M. Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia. JHEOR. 2023;10(2):23-29. doi:10.36469/001c.83240
- Gihan Hamdy Elsisi, Mariam Mohamed El-Attar, Shaimaa Mohamed Ismaeil, et al; Estimation of Prostate Cancer Cost in Egypt From a Societal Perspective. Global Journal on Quality and Safety in Healthcare 1 May 2023; 6 (2): 33–41. doi: https://doi.org/10.36401/JQSH-22-20
- Ahmed Swidan, Gihan Hamdy Elsisi, Mohamed M. Ibrahim, Mohammad Aljazzar & Hossameldin Tawfik Sallam (2023) Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait, Journal of Medical Economics, 26:1, 271-282, DOI: 10.1080/13696998.2023.2174749
- Elsisi GH, Afify A, Abgad A, Zakaria I, Nasif N, Ibrahim HN, Raafat N, Carapinha JL.(2022) A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt. Cost Eff Resour Alloc. 2022 Jan 15;20(1):1. doi: 10.1186/s12962-021-00335-y. PMID: 35033094; PMCID: PMC8760653.
- Abdelhamid M, Elsisi GH, Seyam A, Shafie A, Kirollos M, Emad S, Mansy S, Sobhy M. (2022) Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt. J Med Econ. 2022 Jan-Dec;25(1):450-456. doi: 10.1080/13696998.2022.2054226. PMID: 35291896.
- Elsamany S, Elsisi GH, Mohamed Hassanin FA, Saleh K, Tashkandi E. (2021) Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia. Value Health Reg Issues. 2022 Mar;28:67-75. doi: 10.1016/j.vhri.2021.07.001. Epub 2021 Nov 18. PMID: 34801961.
- Shereef Elsamany, Gihan Hamdy Elsisi, Fayza Hassanin & Mohamed Jafal (2020) Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2- positive breast cancer patients., Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1860024.
- Gihan Hamdy Elsisi, João L. Carapinha , Rania Afify , Mohamed Abd Elmoty & Mohamed Khalaf (2020). A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients, Journal of Medical Economics. DOI: 10.1080/13696998.2020.1796288
- Gihan Hamdy Elsisi, Mohammed Moustapha Anwar, Mohamed Khattab, Ibrahim Elebrashy, Alaa Wafa, Hemat Elhadad, Mohamad Awad & João L. Carapinha (2020). Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt, Journal of Medical Economics. DOI: 10.1080/13696998.2020.1764571
- Gihan Hamdy Elsisi, Yousery Nada, Noha Rashad, João Carapinha, Ahmad O. Noor, Diena M. Almasri, Mostafa Al Zaidy, Ahmed Foad & Hussien Khaled (2019). Cost effectiveness of six months versus 1 year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt, Journal of Medical Economics. https://doi.org/10.1080/13696998.2020.1724682
- Aya Mostafa, Manal H. El-Sayed, Mohamed El Kassas, Manal Elhamamsy, Gihan Hamdy Elsisi. Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries: A Cost-Effectiveness Analysis from Egypt. VALUE IN HEALTH REGIONAL ISSUES 19 (2019) 51 – 8.
- Gihan Hamdy Elsisi, João Carapinha ,Wagdy Amin, Ehab Thabet, Safaa Elafify, Mohamad Amin & Ashraf Hatem (2019) A budget impact analysis of budesonide /formoterol in patients with mild asthma in Egypt, Journal of Medical Economics. https://doi.org/10.1080/13696998.2019.1642899
- Gihan Hamdy Elsisi, Yousery Nada, Noha Rashad & João Carapinha (2018) Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt, Journal of Medical Economics, DOI: 10.1080/13696998.2018.1552432
- Aya Mostafa & Gihan Hamdy Elsisi. A cost-effectiveness analysis of the use of safety-engineered syringes in reducing HBV, HCV, and HIV burden in Egypt, Expert Review of Medical Devices (2018), DOI: 10.1080/17434440.2019.1561267
- Elsayed TM, Elsisi GH, Elmahdawy M, Pharmacy Practice in Egypt. In: Fathelrahman A, Izham M. Pharmacy Practice in Developing Countries: Achievement and Challenges. Academic press, 2016. It can be accessed via Elsevier at: http://store.elsevier.com/product.jsp?isbn=9780128017142
- Gericke CA, Britain K, Elmahdawy M, Elsisi G. The Health System in Egypt. In: E. V. Ginneken, R. Busse (eds.), Health Care Systems and Policies, Health Services Research, New York: Springer, 2018.
- Elmahdawy M, Elsisi GH, Carapinha J et al. Ebola Virus Epidemic in West Africa: Global Health Economic Challenges, Lessons Learned, and Policy Recommendations. Value In Health Regional Issues 13C(2017)67 – 70.
- Elsisi GH, Aburawash A, Waked E. Cost-Effectiveness Analysis of New Hepatitis C Virus Treatments in Egyptian Cirrhotic and Noncirrhotic Patients: A Societal Perspective. Value In Health Regional Issues 13C(2017)7 – 15.
- Elhamamsy MH, Elsisi GH, Eldessouki R, Elmazar MM, Taha AS, Awad BF, Elmansy H. Economic Evaluation of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Mechanical Valve Prostheses. Applied Health Economics and Health Policy Journal 2016; 14: 431.
- Kalo Z, Alabbadi I, Al Ahdab O, Alowayesh M, Elmahdawy M, Al-Saggabi A, Tanzi V, Al-Badriyeh D, Alsultan H, Ali F, Elsisi G, Akhras K, Voko Z and Kanavos P. Implications of external price referencing of pharmaceuticals in Middle 5 East countries. Expert Rev. Pharmacoecon. Outcomes Res. 2015; 15(6).
- Elsisi GH, Eldessouki R, Kaló Z, Elmazar MM, Taha AS, Awad BF, Elhamamsy MH. Cost-Effectiveness of the Combined Use of Warfarin and Low- Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov Model. Value in Health RI 2014: 4C 24-30.
- Elsisi GH, Kaló Z, Eldessouki R, Elmahdawy MD, Saad A, Ragab S, Elshalakani A, Abaza. Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt. Value in Health RI 2013:2;319-327.
- Elsisi G H, Raising Awareness and Improving the Decision-Making Process in Government to Make Better Use of Health Care Resources, ISPOR Connections November/ December 2011,Vol.17. No.6, p.19.
